All News

CURE sat down with Dr. E. Antonio Chiocca to discuss a new brain cancer treatment being studied in an ongoing clinical trial.

Dr. Nadine A. Jackson explains how relatively simple interventions may help close gaps in access to genomics-driven trials across gastrointestinal cancers.

Dr. Ian Flinn explains how subcutaneous Lunsumio VELO uses bispecific antibodies for quick, durable treatment in relapsed/refractory follicular lymphoma.

I live with cancer, but I don’t let it define me. I choose to define my story by courage, trust, and hope.

Prostate cancer survivors Ronald Wakefield and Ernie Strauss sat down for an interview with CURE.

Updated data from GOBLET Cohort 4 demonstrated activity with Reolysin plus Tecentriq in patients with third-line metastatic squamous cell anal carcinoma.

Bill Potts, a five-time cancer survivor, likes to refer to himself as “the luckiest guy I know.”

Joe McDonough shares what message he hopes families hear when first facing a cancer diagnosis.

Dr. Ian Flinn explains how Lunsumio VELO works, offering an outpatient immunotherapy option with accelerated FDA approval.

In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients with BRAF V600E mCRC.

After Donna Rigby visited the emergency department at Hackensack Meridian Jersey Shore University Medical Center, tests showed stage 2 lung cancer.

The U.S. FDA has accepted a supplemental application for Besremi in adults with essential thrombocythemia with an Aug. 30, 2026 action date.

Oya Gilbert blends hip-hop and advocacy to raise awareness about myeloma, engage patients, and address broader health issues in underserved communities.

I share how choosing what to do with my hair during treatment helped me reclaim control and redefine empowerment.

Receiving a diagnosis of stage 1 clear cell renal cell carcinoma can be a shock, but this is the most common and most treatable stage of kidney cancer

Study findings show more colorectal cancer risk reduction and safety with the use of a GLP-1RA versus Aspirin.

I am profoundly, fiercely grateful for every day beyond that harrowing diagnosis. But gratitude is not silence, and survival is not a finish line.

Physical activity, especially walking, was linked to less fatigue and better quality of life for patients with colorectal cancer, particularly in early survivorship.

Tukysa may be a patient-friendly option as a first line maintenance treatment for HER2-positive breast cancer, as Dr. Erika Hamilton explained.

Dr. Thejus Jayakrishnan discussed how patients and physicians weigh treatment options in later-line metastatic colorectal cancer.

The FDA granted fast track designation to Enolen for patients with low-to-intermediate risk prostate cancer.

Mayra Andujar-Delgado shares her 10-year myelofibrosis journey and how 2025 Blood Cancer Hero Dr. Faseeh Khaja empowered her and her husband.

Understanding your diagnosis, the tests ahead and the treatment landscape is the first step in regaining a sense of control.

Lung squamous cell carcinoma starts in airway lining cells; treatment depends on stage, from surgery to systemic therapies, with side effects to monitor.

2025 brought key advances in blood cancer treatment, research, and patient insights across multiple myeloma, lymphoma, leukemia and MDS.

ECOG performance status was found to capture only part of the patient experience in gastric/GEJ adenocarcinoma.

Dr. Elena Elimova discusses how Ziihera-based therapy may change treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma.

These were the top gastrointestinal cancer stories published by CURE in 2025.